<DOC>
	<DOCNO>NCT00355628</DOCNO>
	<brief_summary>This study Phase II open-label study investigate recommend conversion ratio ( oral morphine dose KW-2246 ) switch oral morphine oxycodone KW-2246 cancer patient .</brief_summary>
	<brief_title>Clinical Study KW-2246 Patients With Cancer Pain</brief_title>
	<detailed_description>This study Phase II open-label study investigate , use continual reassessment method procedure pain intensity safety indicator , recommend conversion ratio ( oral morphine dose KW-2246 ) switch oral morphine oxycodone KW-2246 cancer patient maintain oral morphine oral oxycodone pain evaluate safety efficacy KW-2246 .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Provide write informed consent participate study . 2 . Be able hospitalize . 3 . Between age 20 80 year ( inclusive ) time give write informed consent . 4 . Have regularly receive oral morphine oral oxycodone oral morphine equivalent dose 20 120 mg/day least 2 day study entry , AND require rescue dose regular dos . 5 . Not experienced intolerable toxicity 2 day study entry . 6 . Have cancer stable condition study entry expect remain stable KW2246 treatment period . 7 . Have life expectancy least 1 month start KW2246 administration . 8 . Considered able keep patient diary . 1 . Serious respiratory dysfunction . 2 . Asthma . 3 . Serious bradyarrhythmia . 4 . Serious hepatic renal dysfunction . 5 . Susceptibility respiratory depression due condition increase intracranial pressure , head injury brain tumor . 6 . History convulsive seizure ( except single episode infantile febrile convulsion ) . 7 . Current past history drug dependence narcotic abuse . 8 . Dry mouth affect oral intake . 9 . Use opioid analgesic oral morphine oxycodone within 7 day prior study entry . 10 . Use narcotic antagonist within 7 day prior study entry . 11 . Interventions may affect pain evaluation , surgery , radiation pain site ( include site influence pain ) nerve block , within 7 day prior study entry schedule give study . 12 . Patients history serious adverse reaction combination opioid analgesic drugs/substances currently receive expect receive drugs/substances combine opioid analgesic . 13 . History hypersensitivity fentanyl . 14 . Pregnant lactate woman , possibly pregnant woman woman plan become pregnant . 15 . Participation clinical trial within 28 day prior start KW2246 treatment . 16 . Prior exposure KW2246 . 17 . Patients investigator judge unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Continual Reassessment Method</keyword>
	<keyword>Pain Associated Cancer/Neoplasms</keyword>
</DOC>